136 related articles for article (PubMed ID: 52369)
21. Non-cross-resistant combinations in stage IV non-Hodgkin's lymphomas.
Bonadonna G; Monfardini S; Villa E
Cancer Treat Rep; 1977 Sep; 61(6):1117-23. PubMed ID: 71209
[TBL] [Abstract][Full Text] [Related]
22. [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil].
Qin Y; Shi YK; He XH; Yang JL; Yang S; Yu YX; Li B; Wang QL; Zhou LQ; Sun Y
Ai Zheng; 2006 Apr; 25(4):481-5. PubMed ID: 16613685
[TBL] [Abstract][Full Text] [Related]
23. Combined cyclophosphamide vincristine, procarbazine, and prednisone (COPP) therapy of malignant lymphoma. Evaluation of 190 patients.
Morgenfeld MC; Pavlovsky A; Suarez A; Somoza N; Pavlovsky S; Palau M; Barros CA
Cancer; 1975 Oct; 36(4):1241-9. PubMed ID: 1100220
[TBL] [Abstract][Full Text] [Related]
24. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.
Seymour JF; Pro B; Fuller LM; Manning JT; Hagemeister FB; Romaguera J; Rodriguez MA; Ha CS; Smith TL; Ayala A; Hess M; Cox JD; Cabanillas F; McLaughlin P
J Clin Oncol; 2003 Jun; 21(11):2115-22. PubMed ID: 12775737
[TBL] [Abstract][Full Text] [Related]
25. Plasma glutathione S-Transferase P1-1 as a prognostic factor in patients with advanced non-Hodgkin's lymphoma (stages III and IV).
Katahira T; Takayama T; Miyanishi K; Hayashi T; Ikeda T; Takahashi Y; Takimoto R; Matsunaga T; Kato J; Niitsu Y
Clin Cancer Res; 2004 Dec; 10(23):7934-40. PubMed ID: 15585627
[TBL] [Abstract][Full Text] [Related]
26. What is the treatment of choice for advanced-stage Hodgkin's lymphoma: ABVD, Stanford V, or BEACOPP?
Hehn ST; Miller TP
Curr Hematol Rep; 2004 Jan; 3(1):17-26. PubMed ID: 14695845
[TBL] [Abstract][Full Text] [Related]
27. Pediatric Hodgkin's disease.
Oliapuram Jose B; Koerner P; Bertolone S; Patel CC; Spanos WJ; Paris KJ; Silverman CL; Yashar CM
J Ky Med Assoc; 2004 Mar; 102(3):104-6. PubMed ID: 15067795
[TBL] [Abstract][Full Text] [Related]
28. [A retrospective analysis of the treatment results in Hodgkin's disease in a radiotherapy clinic].
Mjaaland I; Ganser D; Freitag EM; Bohndorf W
Strahlenther Onkol; 1994 Sep; 170(9):516-23. PubMed ID: 7524173
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy of advanced malignant lymphomas comparative evaluation of results with single agent and combination therapy.
Klener P; Donner L; Roth Z
Neoplasma; 1976; 23(3):315-22. PubMed ID: 958533
[TBL] [Abstract][Full Text] [Related]
30. Comparison of two non-cross-resistant combinations (ABVP/LOPP) with COPP plus bleomycin in the treatment of advanced Hodgkin's disease.
Koza I; Bohunický L; Mociková K; Gyárfás J; Svancárová L; Mardiak J; Spánik S; Fuchsberger P; Thalmeinerová Z; Sufliarsky J
Neoplasma; 1991; 38(6):583-93. PubMed ID: 1722564
[TBL] [Abstract][Full Text] [Related]
31. Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup.
Anderson T; Bender RA; Fisher RI; DeVita VT; Chabner BA; Berard CW; Norton L; Young RC
Cancer Treat Rep; 1977 Sep; 61(6):1057-66. PubMed ID: 71205
[No Abstract] [Full Text] [Related]
32. [Malignant non-hodgkinian hematosarcomas (lymphomae) in the adult. Chemoradiotherapy applied to stages and/or topographic forms III and IV].
Pouillart P; Hayat M; Gérard-Marchant R; Schlumberger JR; Amiel JL; Mathé A; Tubiana M
Bull Cancer; 1974; 61(1):111-8. PubMed ID: 4142403
[No Abstract] [Full Text] [Related]
33. [Chemotherapy in non-Hodgkin's lymphomas (author's transl)].
Schmidt CG
Strahlentherapie; 1977 May; 153(5):283-92. PubMed ID: 69343
[TBL] [Abstract][Full Text] [Related]
34. European experience with ifosfamide in lymphomas.
von Kalle AK; Schaadt M; Diehl V
Semin Oncol; 1989 Feb; 16(1 Suppl 3):73-7. PubMed ID: 2468184
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy of non-Hodgkin's lymphomas: Eastern Cooperative Oncology Group experience.
Bennett JM; Lenhard RE; Ezdinli E; Johnson GJ; Carbone PP; Pocock SJ
Cancer Treat Rep; 1977 Sep; 61(6):1079-83. PubMed ID: 71207
[TBL] [Abstract][Full Text] [Related]
36. Proceedings: Malignant lymphoma: treatment with combination chemotherapy.
De Vita VT; Canellos GP; Schein PJ; Chabner BA; Bagley CM; Young RC
Proc Natl Cancer Conf; 1972; 7():379-90. PubMed ID: 4587651
[No Abstract] [Full Text] [Related]
37. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
[TBL] [Abstract][Full Text] [Related]
38. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
39. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.
Federico M; Luminari S; Iannitto E; Polimeno G; Marcheselli L; Montanini A; La Sala A; Merli F; Stelitano C; Pozzi S; Scalone R; Di Renzo N; Musto P; Baldini L; Cervetti G; Angrilli F; Mazza P; Brugiatelli M; Gobbi PG;
J Clin Oncol; 2009 Feb; 27(5):805-11. PubMed ID: 19124807
[TBL] [Abstract][Full Text] [Related]
40. Impressive response to temsirolimus in a patient with chemotherapy refractory diffuse large B-cell non-Hodgkin's lymphoma.
Kiewe P; Thiel E
Ann Hematol; 2011 Jan; 90(1):109-10. PubMed ID: 20387065
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
